{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:36:10Z","timestamp":1788870970198,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:00:00Z","timestamp":1277078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7,1]]},"abstract":"<jats:p>This article examines the role of real-time quantitative polymerase chain reaction testing of BCR-ABL transcript levels to assess minimal residual disease and outcomes in patients with chronic myeloid leukemia.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0055","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T22:15:35Z","timestamp":1277158535000},"page":"744-749","source":"Crossref","is-referenced-by-count":10,"title":["Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy"],"prefix":"10.1093","volume":"15","author":[{"given":"Richard D.","family":"Press","sequence":"first","affiliation":[{"name":"Knight Cancer Institute and Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,6,21]]},"reference":[{"key":"2021122207515759900_R1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122207515759900_R2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515759900_R3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2021122207515759900_R4","article-title":"NCCN: Clinical Practice Guidelines in Oncology","volume-title":"Chronic Myelogenous Leukemia, Version 2","author":"National Comprehensive Cancer Network","year":"2010"},{"key":"2021122207515759900_R5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122207515759900_R6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207515759900_R7","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122207515759900_R8","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"key":"2021122207515759900_R9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207515759900_R10","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"2021122207515759900_R11","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122207515759900_R12","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122207515759900_R13","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"2021122207515759900_R14","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"2021122207515759900_R15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2021122207515759900_R16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"2021122207515759900_R17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"2021122207515759900_R18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: Molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122207515759900_R19","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"2021122207515759900_R20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.LBA-1.LBA-1","article-title":"Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: Results from the international randomized phase III ENESTnd trial","volume":"114","author":"Saglio","year":"2009","journal-title":"Blood"},{"key":"2021122207515759900_R21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2009.156","article-title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: Response dynamics and predictive value","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"2021122207515759900_R22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood.V114.22.3292.3292","article-title":"Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) [abstract 3292]","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"2021122207515759900_R23","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515759900_R24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: A report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"J Mol Diagn"},{"key":"2021122207515759900_R25","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"2021122207515759900_R26","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207515759900_R27","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"2021122207515759900_R28","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0055","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/7\/744\/41843632\/oncolo_15_7_744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/7\/744\/41843632\/oncolo_15_7_744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:52:58Z","timestamp":1640152378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/7\/744\/6399408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,21]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,6,21]]},"published-print":{"date-parts":[[2010,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0055","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,7,1]]},"published":{"date-parts":[[2010,6,21]]}}}